BioAge Labs has dosed the first participant in its Phase 2 QUELL-CV trial testing BGE-102, a new oral NLRP3 inhibitor aimed at reducing cardiovascular risk by lowering systemic inflammation. The randomized, placebo-controlled study will evaluate three doses over 12 weeks in about 160 adults with obesity and elevated inflammation. The primary goal is to measure changes in hsCRP, a key inflammation marker linked to heart disease. Positive Phase 1 results showed strong hsCRP reductions and good tolerance, and topline Phase 2 data are expected in late 2026. This trial will guide dose selection for Phase 3 and supports further development of BGE-102 for cardiovascular and retinal diseases.
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
Aehr Test Systems is shifting its semiconductor testing business towards AI processors and data centers, driving strong growth prospects. The company reported $18.8 million in Q4 revenue, up from $14.1 million last year, and a net income turnaround t...
